Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity

Biomaterials

Volumn 33, Issue 32, 2012, Pages 8104-8110

  Guo, Peng ^a   You, Jin Oh ^a   Yang, Jiang ^b,c   Moses, Marsha A ^b,c   Auguste, Debra T ^a,b,c  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Breast cancer; CXCR4; Doxorubicin; Drug delivery; Liposome; Targeted delivery

Indexed keywords

BONE MARROW; BREAST CANCER; BREAST CANCER CELLS; CELL CHARACTERIZATION; CHEMOKINE RECEPTORS; CHEMOKINES; CXCR4; DOXORUBICIN; INVASIVENESS; LYMPH NODE; SIDE EFFECT; SURFACE EXPRESSION; SURFACE RECEPTORS; TARGETED DELIVERY;

CELL CULTURE; CELL DEATH; DISEASES; DRUG DELIVERY; LIPOSOMES;

GENE EXPRESSION;

1,2 DIOLEOYL GLYCERO 3 PHOSPHOETHANOLAMINE N DODECANOYL; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 MONOCLONAL ANTIBODY; DIOLEOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; LIPOSOME; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG TARGETING; ENCAPSULATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; RECEPTORS, CXCR4;

EID: 84865550238     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.07.043     Document Type: Article

References (37)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J Clin 2012, 62:10-29.
2. Cardoso F., Senkus-Konefka E., Fallowfield L., Costa A., Castiglione M. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21:15-19.
3. Hickey R.C., Gallager H.S., Dodd G.D., Samuels B.I., Paulus D.D., Moore D.L. The detection and diagnosis of early, occult and minimal breast cancer. Adv Surg 1976, 10:287-312.
4. Weigelt B., Peterse J.L., van't Veer L.J. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005, 5:591-602.
5. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001, 344:783-792.
6. Fossati R., Confalonieri C., Torri V., Ghislandi E., Penna A., Pistotti V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998, 16:3439-3460.
7. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New Engl J Med 2006, 355:2733-2743.
8. Vogel C.L. Efficacy and Safety of Trastuzumab as a Single Agent in First-line treatment of HER2-Overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
9. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
10. Wu B., Chien E.Y.T., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330:1066-1071.
11. Epstein R.J. Opinion: the CXCL12-CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies. Nat Rev Cancer 2004, 4:901-909.
12. D'Arpa P., Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim Biophys Acta 1989, 989:163-177.
13. Frederick C.A., Williams L.D., Ughetto G., Van der Marel G.A., Van Boom J.H., Rich A., et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 1990, 29:2538-2549.
14. Tardi P.G., Boman N.L., Cullis P.R. Liposomal doxorubicin. J Drug Target 1996, 4:129-140.
15. Cho H.-S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
16. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004, 64:6652-6659.
17. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958-3965.
18. Owens M.A., Horten B.C., Da Silva M.M. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004, 5:63-69.
19. Qian Z.M. Targeted drug delivery via the transferrin receptor-Mediated Endocytosis pathway. Pharmacol Rev 2002, 54:561-587.
20. Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin 2007, 28:1476-1493.
21. Prindull G., Zipori D. Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm. Blood 2004, 103:2892-2899.
22. Przybylo J.A., Radisky D.C. Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007, 39:1082-1088.
23. Gunawan R.C., Almeda D., Auguste D.T. Complementary targeting of liposomes to IL-1α and TNF-α activated endothelial cells via the transient expression of VCAM1 and E-selectin. Biomaterials 2011, 32:9848-9853.
24. Gunawan R.C., Auguste D.T. Immunoliposomes that target endothelium in vitro are dependent on lipid raft formation. Mol Pharmaceutics 2010.
25. Gunawan R.C., Auguste D.T. The role of antibody synergy and membrane fluidity in the vascular targeting of immunoliposomes. Biomaterials 2010, 31:900-907.
26. Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Barenholz Y., et al. Ammonium sulfate gradients for efficient and Stable Remote loading of Amphipathic Weak Bases into liposomes and Ligandoliposomes. J Liposome Res 1994, 4:455-479.
27. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009, 30:592-599.
28. Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., et al. Molecular Profiling of breast cancer cell lines Defines Relevant tumor models and Provides a Resource for cancer gene Discovery. Plos One 2009, 4. e6146.
29. Smith M.C.P. CXCR4 Regulates growth of both primary and metastatic breast cancer. Cancer Res 2004, 64:8604-8612.
30. Gul H., Marquez-Curtis L.A., Jahroudi N., Lo J., Turner A.R., Janowska-Wieczorek A. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev 2009, 18:831-838.
31. Lee B. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci 1999, 96:5215-5220.
32. Mahmud N., Patel H., Hoffman R. Growth factors mobilize CXCR4 low/negative primitive hematopoietic stem/progenitor cells from the bone marrow of nonhuman primates. Biol Blood Marrow Transplant 2004, 10:681-690.
33. Karukstis K.K., Thompson E.H., Whiles J.A., Rosenfeld R.J. Deciphering the fluorescence signature of daunomycin and doxorubicin. Biophys Chem 1998, 73:249-263.
34. You J.-O., Almeda D., Ye G.J.C., Auguste D.T. Bioresponsive matrices in drug delivery. J Biol Eng 2010, 4:15.
35. You J.-O., Auguste D.T. Nanocarrier Cross-Linking density and pH Sensitivity Regulate intracellular gene transfer. Nano Lett 2009, 9:4467-4473.
36. You J.-O., Auguste D.T. The effect of swelling and cationic character on gene transfection by pH-sensitive nanocarriers. Biomaterials 2010, 31:6859-6866.
37. You J.-O., Auguste D.T. Feedback-regulated paclitaxel delivery based on poly(N,N-dimethylaminoethyl methacrylate-co-2-hydroxyethyl methacrylate) nanoparticles. Biomaterials 2008, 29:1950-1957.